Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Primary objective
- To determine the clinical prognosis by identifying the disease course and severity by treatment with or without eculizumab in patients with aHUS in Korea.
Secondary objectives
As a retrospective, non-interventional, multi-center study
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Clinical prognosis (Renal survival) by treatment with or without eculizumab | Renal survival (end-stage renal disease [ESRD]-free survival) | from the first onset date of TMA diagnosed as aHUS to the last follow up (within March 31, 2022), death, or date of ESRD diagnosis, whichever came first |
| Clinical prognosis (Overall survival) by treatment with or without eculizumab | Overall survival (OS) | from the first onset date of TMA diagnosed as aHUS to the last follow up (within March 31, 2022), death, whichever came first |
| Measure | Description | Time Frame |
|---|---|---|
| Clinical prognosis (Renal survival) of all aHUS patients in Korea | Renal survival (ESRD-free survival) | from the first onset date of TMA diagnosed as aHUS to the last follow up (within March 31, 2022), death, or date of ESRD diagnosis, whichever came first |
| Clinical prognosis (Overall survival) of all aHUS patients in Korea |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Patients who are clinically diagnosed with the atypical hemolytic uremic syndrome (aHUS).
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Handok | Seoul | South Korea |
Not provided
Not provided
Not provided
Not provided
Overall survival (OS) |
| from the first onset date of TMA diagnosed as aHUS to the last follow up (within March 31, 2022), death, whichever came first |
| Clinical prognosis (Renal survival) of patients diagnosed with aHUS prior to the initiation of eculizumab reimbursement system in Korea | Renal survival (ESRD-free survival) | from the first onset date of TMA diagnosed as aHUS to the last follow up (within March 31, 2022), death, or date of ESRD diagnosis, whichever came first |
| Clinical prognosis (Overall survival) of patients diagnosed with aHUS prior to the initiation of eculizumab reimbursement system in Korea | Overall survival (OS) | from the first onset date of TMA diagnosed as aHUS to the last follow up (within March 31, 2022), death, whichever came first |
| Response rates of each treatment, compared to prior to start treatment | Complete response of TMA | 3rd and 6th months |